CAPR: Capricor Therapeutics Inc
Company identity verified 2026-11-20. Current quotes, news, filings and options load in the terminal; unavailable data is left unavailable.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs.
| Primary exchange (MIC) | XNAS |
|---|---|
| Listed since | 2002-06-20 |
| Market capitalization | $437.8 million |
| Shares outstanding | 58,142,114 |
| Employees | 231 |
| Headquarters | SAN DIEGO, CA, US |
| Website | www.capricor.com |
CAPR has traded between $7.38 and $8.34 in the current session, a range of $0.96. The latest price of $1.65 sits near the bottom of that range (-593% of the way from low to high). It opened at $7.64, a gap up of 1.46% from the prior close of $7.53.
| Open | $7.64 |
|---|---|
| High | $8.34 |
| Low | $7.38 |
| Previous close | $7.53 |
| Volume | 20,056,476 |
StockMarketLoop's Market Position model estimates how the shares traded between 2026-08-23 and 2026-11-21 were bought. Its estimate of the average cost basis is $8.42; at $1.65 the stock trades 80.4% below that level. About 24.3% of those shares are estimated to be held at a profit at the current price. A low figure means most recent buyers are underwater, so rallies can meet selling from holders trying to get back to break even. The densest nearby clusters of cost basis sit around $7.48 (support) and $8.31 (resistance). Roughly 70% of the estimated cost basis lies between $7.06 and $9.75, and 90% between $6.23 and $10.49.
This is a model estimate built from price and volume history, not a record of actual positions.
Quote figures come from StockMarketLoop's market data feed and may be delayed; the timestamp in the summary above shows when they were observed. Company details come from public reference data. The cost-basis section is a statistical model, not a forecast. Nothing here is investment advice; see our financial disclaimer and editorial policy.
Company identity verified 2026-11-20. Current quotes, news, filings and options load in the terminal; unavailable data is left unavailable.